Matsudaira et al. reported that SSA Ab is an independent factor associated with insufficient response to TNFi therapy in RA patients but that positive rate and titers of SSA Ab did not change during the therapy, while ANA and dsDNA Ab titers were increased from baseline [19]. The gene discussed is BTG3; the disease is rheumatoid arthritis.